Innovent Biologics Valuation
| IVBXF Stock | USD 4.86 0.03 0.62% |
At this time, the firm appears to be overvalued. Innovent Biologics retains a regular Real Value of $4.32 per share. The prevalent price of the firm is $4.86. Our model calculates the value of Innovent Biologics from evaluating the firm fundamentals such as Current Valuation of 5.13 B, return on equity of -0.29, and Return On Asset of -0.14 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Innovent Biologics' price fluctuation is relatively risky at this time. Calculation of the real value of Innovent Biologics is based on 3 months time horizon. Increasing Innovent Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Innovent pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Innovent Biologics. Since Innovent Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Innovent Pink Sheet. However, Innovent Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.86 | Real 4.32 | Hype 4.86 |
The real value of Innovent Pink Sheet, also known as its intrinsic value, is the underlying worth of Innovent Biologics Company, which is reflected in its stock price. It is based on Innovent Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Innovent Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Innovent Biologics helps investors to forecast how Innovent pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Innovent Biologics more accurately as focusing exclusively on Innovent Biologics' fundamentals will not take into account other important factors: Innovent Biologics Total Value Analysis
Innovent Biologics is currently anticipated to have takeover price of 5.13 B with market capitalization of 8.37 B, debt of 2.02 B, and cash on hands of 8.32 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Innovent Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.13 B | 8.37 B | 2.02 B | 8.32 B |
Innovent Biologics Investor Information
About 44.0% of the company shares are owned by institutional investors. The book value of Innovent Biologics was currently reported as 6.54. The company recorded a loss per share of 0.32. Innovent Biologics had not issued any dividends in recent years. Based on the key indicators related to Innovent Biologics' liquidity, profitability, solvency, and operating efficiency, Innovent Biologics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Innovent Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Innovent Biologics has an asset utilization ratio of 26.29 percent. This implies that the Company is making $0.26 for each dollar of assets. An increasing asset utilization means that Innovent Biologics is more efficient with each dollar of assets it utilizes for everyday operations.Innovent Biologics Ownership Allocation
Innovent Biologics has a total of 1.53 Billion outstanding shares. 30% of Innovent Biologics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Innovent Biologics Profitability Analysis
The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Innovent Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Innovent Biologics and how it compares across the competition.
About Innovent Biologics Valuation
The pink sheet valuation mechanism determines Innovent Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Innovent Biologics. We calculate exposure to Innovent Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Innovent Biologics's related companies.Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.
8 Steps to conduct Innovent Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Innovent Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Innovent Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Innovent Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Innovent Biologics' revenue streams: Identify Innovent Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Innovent Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Innovent Biologics' growth potential: Evaluate Innovent Biologics' management, business model, and growth potential.
- Determine Innovent Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Innovent Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Innovent Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Innovent Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 B | |
| Retained Earnings | -13.1 B |
Complementary Tools for Innovent Pink Sheet analysis
When running Innovent Biologics' price analysis, check to measure Innovent Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovent Biologics is operating at the current time. Most of Innovent Biologics' value examination focuses on studying past and present price action to predict the probability of Innovent Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovent Biologics' price. Additionally, you may evaluate how the addition of Innovent Biologics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |